 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
2 terms
|
 |
|
Biological process
|
immune response
|
5 terms
|
 |
|
Biochemical function
|
cytokine activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
40:12486-12496
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Monomeric solution structure of the prototypical 'C' chemokine lymphotactin.
|
|
E.S.Kuloglu,
D.R.McCaslin,
M.Kitabwalla,
C.D.Pauza,
J.L.Markley,
B.F.Volkman.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Lymphotactin, the sole identified member of the C class of chemokines,
specifically attracts T lymphocytes and natural killer cells. This 93-residue
protein lacks 2 of the 4 conserved cysteine residues characteristic of the other
3 classes of chemokines and possesses an extended carboxyl terminus, which is
required for chemotactic activity. We have determined the three-dimensional
solution structure of recombinant human lymphotactin by NMR spectroscopy. Under
the conditions used for the structure determination, lymphotactin was
predominantly monomeric; however, pulsed field gradient NMR self-diffusion
measurements and analytical ultracentrifugation revealed evidence of dimer
formation. Sequence-specific chemical shift assignments were determined through
analysis of two- and three-dimensional NMR spectra of (15)N- and
(13)C/(15)N-enriched protein samples. Input for the torsion angle dynamics
calculations used in determining the structure included 1258 unique NOE-derived
distance constraints and 60 dihedral angle constraints obtained from
chemical-shift-based searching of a protein conformational database. The
ensemble of 20 structures chosen to represent the structure had backbone and
heavy atom rms deviations of 0.46 +/- 0.11 and 1.02 +/- 0.14 A, respectively.
The results revealed that human lymphotactin adopts the conserved chemokine
fold, which is characterized by a three-stranded antiparallel beta-sheet and a
C-terminal alpha-helix. Two regions are dynamically disordered as evidenced by
(1)H and (13)C chemical shifts and [(15)N]-(1)H NOEs: residues 1-9 of the amino
terminus and residues 69-93 of the C-terminal extension. A functional role for
the C-terminal extension, which is unique to lymphotactin, remains to be
elucidated.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.L.Salanga,
and
T.M.Handel
(2011).
Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function.
|
| |
Exp Cell Res, 317,
590-601.
|
 |
|
|
|
|
 |
M.M.Stratton,
and
S.N.Loh
(2011).
Converting a protein into a switch for biosensing and functional regulation.
|
| |
Protein Sci, 20,
19-29.
|
 |
|
|
|
|
 |
P.N.Bryan,
and
J.Orban
(2010).
Proteins that switch folds.
|
| |
Curr Opin Struct Biol, 20,
482-488.
|
 |
|
|
|
|
 |
C.Camilloni,
and
L.Sutto
(2009).
Lymphotactin: how a protein can adopt two folds.
|
| |
J Chem Phys, 131,
245105.
|
 |
|
|
|
|
 |
H.R.Lüttichau
(2008).
The herpesvirus 8 encoded chemokines vCCL2 (vMIP-II) and vCCL3 (vMIP-III) target the human but not the murine lymphotactin receptor.
|
| |
Virol J, 5,
50.
|
 |
|
|
|
|
 |
R.L.Tuinstra,
F.C.Peterson,
S.Kutlesa,
E.S.Elgin,
M.A.Kron,
and
B.F.Volkman
(2008).
Interconversion between two unrelated protein folds in the lymphotactin native state.
|
| |
Proc Natl Acad Sci U S A, 105,
5057-5062.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.T.Veldkamp,
F.C.Peterson,
P.L.Hayes,
J.E.Mattmiller,
J.C.Haugner,
N.de la Cruz,
and
B.F.Volkman
(2007).
On-column refolding of recombinant chemokines for NMR studies and biological assays.
|
| |
Protein Expr Purif, 52,
202-209.
|
 |
|
|
|
|
 |
H.R.Lüttichau,
A.H.Johnsen,
J.Jurlander,
M.M.Rosenkilde,
and
T.W.Schwartz
(2007).
Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3.
|
| |
J Biol Chem, 282,
17794-17805.
|
 |
|
|
|
|
 |
R.L.Tuinstra,
F.C.Peterson,
E.S.Elgin,
A.J.Pelzek,
and
B.F.Volkman
(2007).
An engineered second disulfide bond restricts lymphotactin/XCL1 to a chemokine-like conformation with XCR1 agonist activity.
|
| |
Biochemistry, 46,
2564-2573.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Y.Yount,
A.S.Bayer,
Y.Q.Xiong,
and
M.R.Yeaman
(2006).
Advances in antimicrobial peptide immunobiology.
|
| |
Biopolymers, 84,
435-458.
|
 |
|
|
|
|
 |
F.C.Peterson,
E.S.Elgin,
T.J.Nelson,
F.Zhang,
T.J.Hoeger,
R.J.Linhardt,
and
B.F.Volkman
(2004).
Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin.
|
| |
J Biol Chem, 279,
12598-12604.
|
 |
|
|
|
|
 |
G.J.Swaminathan,
D.E.Holloway,
R.A.Colvin,
G.K.Campanella,
A.C.Papageorgiou,
A.D.Luster,
and
K.R.Acharya
(2003).
Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine.
|
| |
Structure, 11,
521-532.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.S.Kuloğlu,
D.R.McCaslin,
J.L.Markley,
and
B.F.Volkman
(2002).
Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditions.
|
| |
J Biol Chem, 277,
17863-17870.
|
 |
|
|
|
|
 |
P.H.Carter
(2002).
Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong?
|
| |
Curr Opin Chem Biol, 6,
510-525.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|